Table 1. SARS-CoV-2 antibody seroprevalence test results by age group in cross-sectional survey, Omdurman, Sudan*.
| Age group | RDT results |
Adjusted results |
|||||
|---|---|---|---|---|---|---|---|
| % Positive (95% CI) | Relative risk (95% CI) | p value† | Seroprevalence (95% CI) | Relative risk (95% CI) | p value† | ||
| <5 y, = 299 | 18.7 (14.7–23.5) | 0.4 (0.3–0.5) | <0.001 | 29.0 (22.4–36.9) | 0.3 (0.3–0.4) | <0.001 | |
| 5–19 y, = 786 | 30.6 (27.5–33.9) | 0.6 (0.5–0.7) | <0.001 | 48.5 (43.3–53.9) | 0.6 (0.5–0.6) | <0.001 | |
| 20–34 y, = 629 | 35.5 (31.8–39.3) | 0.7 (0.6–0.8) | <0.001 | 56.5 (50.5–62.8) | 0.7 (0.6–0.7) | <0.001 | |
| 35–49 y, = 342 | 39.5 (34.4–44.7) | 0.8 (0.7–0.9) | 0.006 | 63.1 (54.8–71.8) | 0.8 (0.7–0.9) | <0.001 | |
|
>50 y, = 319 |
50.2 (44.7–55.6) |
Referent |
|
80.7 (71.7–89.7) |
Referent |
||
| Overall, = 2,375 | 34.3 (32.4–36.2) |
|
54.6 (51.4–57.8) |
|
|||
*RDT, rapid diagnostic test; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. †p values indicate the difference in relative risk between the oldest age group (≥50 y) as reference and the other age groups.